Reading RNAZ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RNAZ free→Reading RNAZ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RNAZ free→QuarterlyIQ Insights · RNAZ
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 3, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing further results of its Phase 1a dose escalation clinical trial with TTX-MC138. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without l…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On May 19, 2026, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed o…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On May 19, 2026, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed o…
Acquisition PIK Dividend As previously disclosed by the Company, on October 8, 2025, the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with DEFJ, LLC, a Delaware limited liability company (“DEFJ”), pursuant to which the Company acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company (“ABCJ”) (such transaction, the “Acquisition”). Prior to the Acquisition, ABCJ was a wholly owned subsidiary o…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Entry into a Material Definitive Agreement. On April 6, 2026 , TransCode Therapeutics, Inc., a Delaware corporation, (the “Company,” “we,” or “our”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited partnership (“Yorkville”), pursuant to which the Company has the right to sell to Yorkville up to $14 million of shares of the Company’s common stock, par value $0.0001 per share, (“Common Stock”) subject to certain limitations and co…
Unregistered Sales of Equity Securities. The information contained in
Other Information On March 2, 2026, the Company, entered into an Exclusive Licensing Agreement (the “Licensing Agreement”) with Unleash Immuno Oncolytics, Inc., a Delaware corporation (“Unleash”), pursuant to which the Company acquired a pre-clinical candidate program involving genetically-engineered adenoviruses to harness the immune system to fight cancer, as well as an exclusive, perpetual, irrevocable, worldwide, fully-paid up, royalty-free, sublicensable right and license to related tech…
of Form 8-K, the information contained in Items 5.03 and 8.01 of this Current Report on Form 8-K is incorporated by reference into this
Regulation FD Disclosure. On February 5, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing, in collaboration with Quantum Leap Healthcare Collaborative, the submission to the U.S. Food and Drug Administration of an Investigational New Drug application amendment for a planned Phase 2a clinical trial with TransCode’s lead therapeutic candidate, TTX-MC138. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The informatio…
Other Events. Risks Related to the Acquisition and Investment There are a number of risks related to the Acquisition and Investment, including the risk factors enumerated below. Accordingly, the Company is providing these additional risk factors to supplement the risks described in “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, and othe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment On December 19, 2025, the Board of Directors (the “Board”) of TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Jack Stover to the Board, effective December 19, 2025. Mr. Stover will serve with a term expiring…
Regulation FD Disclosure. On December 11, 2025, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing a new collaboration to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, as part of the Quantum Leap Healthcare Collaborative (“Quantum Leap”) PRE-I-SPY clinical trial platform. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished herew…
Material Modification to Rights of Securityholders. To the extent required by
Entry into a Material Definitive Agreement. Contingent Value Rights Agreement Effective as of October 8, 2025, the Company entered into a Contingent Value Rights Agreement (the “CVR Agreement”) with Vstock Transfer, LLC as rights agent (the “Rights Agent”), pursuant to which each holder of Common Stock as of as of 5:00 p.m. Eastern Time on October 20, 2025, including those holders receiving shares of Common Stock in connection with the Acquisition, is entitled to one contractual contingent va…
Other Events. On October 14, 2025, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing completion of its Phase 1a clinical trial with TTX-MC138. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. A copy of the related poster is attached hereto as Exhibit 99.2 and incorporated herein by reference. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the…
Pursuant to the Purchase Agreement and Investment Agreement, the Company issued shares of Common Stock and Preferred Stock to DEFJ, which represented that it was an “accredited investor,” as defined in Regulation D of the Securities Act, and was acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof . Such issuances were exempt from the registration requirements of the Securities Act in reliance on Se…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment On October 6, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Elizabeth Czerepak to the Board, effective October 8, 2025. Ms. Czerepak will serve with a term expiring at the Company’s annual meeting of stockholders to be held in 2026, at which time she is expected to stand f…
8 Forward Looking Statements Any statements in this Current Report on Form 8-K about the future expectations, plans and prospects of the Company, including without limitation, statements regarding: the Acquisition, the Investment, stockholder approval of the conversion of Preferred Stock and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “wo…
by reference. The foregoing descriptions of the Acquisition, the Investment, the Purchase Agreement and the Investment Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Purchase Agreement and Investment Agreement, copies of which are filed as Exhibit 2.1 and Exhibit 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The Purchase Agreement and the Investment Agreement have been filed he…
of Form 8-K, the information contained in Items 1.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this
Entry into a Material Definitive Agreement. On September 30, 2025, TransCode Therapeutics, Inc. (the “Company”) and The General Hospital Corporation d/b/a Massachusetts General Hospital (the “Licensor”) entered into the Second Amendment to Exclusive Patent License Agreement (the “Second Amendment”) to that certain Exclusive Patent License Agreement, dated October 26, 2018, and amended by the First Amendment to Exclusive Patent License Agreement, dated October 30, 2020, (as so amended, the “MG…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2025, TransCode Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that, for the 30 consecutive business day period between March 24, 2025, through May 5, 2025, the Company’s common stock had not maintained a minimum closing bid price of $1.00 per shar…
of Form 8-K, information regarding the Reverse Split (as defined below) contained in
Other Events. On April 21, 2025, TransCode Therapeutics, Inc. (the “Company”) convened a special meeting of stockholders (the “Special Meeting”) to vote upon the proposals set forth in the definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 11, 2025 (the “Proxy Statement”). There were 2,972,800 shares of the Company’s common stock, par value $0.0001, present or represented by proxy at the Special Meeting, which did not constitut…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.